Illumina is going beyond the sequencer, developing transformative technologies that empower researchers to explore biology with unprecedented depth and dimension.
In this session, we unveil breakthrough innovations that accelerate insights in single-cell.
Illumina Single Cell 3' RNA Prep, the first Illumina scRNA-seq kit, is designed to scale to million cell reactions. In addition to enabling huge single cell transcriptomics studies, this unlocks our upcoming CRISPR kit to enable high-powered perturb seq studies made practical by the unmatched throughput of NovaSeq X and the speed of DRAGEN analysis.

Sheila Dodge, MLA, MBA
Chief Operating Officer, Broad Clinical Labs
Sr Dir, Strategic Financial Operations, Platforms; Institute Scientist, The Broad
Your email address is never shared with third parties.